The current standard of care in haemophilia A (HA) is treatment with exogenous coagulation factor VIII (FVIII) concentrates, which may be plasma-derived (pdFVIII) or produced using recombinant cell technology (rFVIII). The gene discussed is F8; the disease is hemophilia A.